A recent report by the Paragon Health Institute has drawn renewed attention to enrollment irregularities within the Affordable Care Act (ACA) marketplace, estimating that approximately 6.2 million people were improperly enrolled in 2026. The report, co-authored by Paragon’s president Brian Blase, highlights the financial implications for taxpayers as insurers collect tens of billions of dollars annually in subsidies intended for qualified individuals.

Improper enrollment in this context refers primarily to recipients of the largest exchange subsidies who do not meet eligibility criteria. Blase defended the findings against critiques that challenge the scope of the problem, noting that the estimate is likely conservative due to conservative methodologies. He cited comments from Mehmet Oz, head of the Centers for Medicare and Medicaid Services (CMS), who indicated during a White House briefing that CMS believes roughly one-third of ACA enrollments may be improper.

CMS has taken steps to reduce ineligible participation, removing approximately 1.5 million individuals from the exchange rolls, but Blase emphasized that this action underlines the persistence of the issue rather than resolving it. Some enrolled individuals may be unaware of their status or are covered by other insurance plans. Paragon’s report also points to the economic incentives fueling improper enrollment, with insurers and brokers financially benefiting from increased enrollment, particularly following congressional expansions of subsidies and introduction of zero-premium plans.

In related policy debates, experts urge caution in approaching reforms to the Supplemental Nutrition Assistance Program (SNAP). Anne Filipic, CEO of Share Our Strength, and Crystal FitzSimons, president of the Food Research & Action Center, argue that observed payment errors largely reflect administrative challenges rather than fraudulent activity. They stress that shifting the financial burden of these errors to already budget-strapped states could result in cuts to vital services or reduced SNAP access. Both advocate for investments in modernization, improved data systems, and protective measures such as chip-enabled benefit cards to enhance program integrity without penalizing beneficiaries.

Regulation of consumer health products also remains a focus, particularly regarding the Food and Drug Administration’s (FDA) review processes. Paul C. Brown, a former FDA associate director, defended the agency’s rigorous safety and efficacy standards for sunscreen products. Brown noted that the FDA’s requirement for comprehensive data before approving ingredients like bemotrizinol contrasts with more lenient international standards. He cited enzacamene, a sunscreen ingredient banned in Europe due to safety concerns, as an example underscoring the prudence of the FDA’s cautious approach.

Meanwhile, scrutiny of the food industry’s role in public health continues amid discussions about its influence on dietary habits. Alexa Marsh, a public health advocate, called for greater regulatory attention to ultra-processed foods, drawing parallels to historical actions taken against tobacco companies. She suggested that the United States could benefit from adopting strategies employed by countries such as Chile, Mexico, and Canada, which have implemented evidence-based policies to encourage healthier and more sustainable consumption patterns.